Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4add7e8af694d8c07c2659fe21e093c5 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-12 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-337 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-127 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1271 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-28 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-337 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127 |
filingDate |
2016-02-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c73c1bf15509a00263a85a41419d7f9b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e9d8c439e58836b315b0059f5489e780 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8d0a70f4afb0393d35a95137cd45ea9f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_efb8250a3e153ad913e30719b969283b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ed3a4e7bbf90308725b39e58a1354c3f |
publicationDate |
2016-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2016250177-A1 |
titleOfInvention |
Modified docetaxel liposome formulations and uses thereof |
abstract |
The present invention provides compositions for the treatment of cancer. The compositions include liposomes containing a phosphatidylcholine lipid, a sterol, a PEG-lipid, and a taxane. The PEG-lipid constitutes from about 2 to about 8 mol % of the lipids in the liposome. The taxane is docetaxel esterified at the 2′-O position with a heterocyclyl-(C 2-5 alkanoic acid). The present invention also provides liposomal compositions for the treatment of cancer comprising administering to a patient in need thereof a liposome, wherein the liposome comprises: a phosphatidylcholine lipid; a sterol; a PEG-lipid; and a taxane or a pharmaceutically acceptable salt thereof; wherein the taxane is docetaxel esterified at the 2′-O-position with a heterocyclyl-(C 2-5 alkanoic acid); and wherein upon administration of the liposomal composition to the patient, the plasma concentration of docetaxel remain above an efficacy threshold of 0.2 μM for at least 5 hours. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2023287020-A1 |
priorityDate |
2015-02-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |